研究業績
令和1年度（2019年度）
医学医療系業績
1. Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, Nishina T, Esaki T, Hasegawa J, Kakurai Y, Kamiyama E, Nakata T, Nakamura K, Sakaki H, Hyodo I. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. J Immunother Cancer. 2019 Aug 14;7(1):219.
2. Yamada Y, Koizumi W, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Cancer Sci. 2019 Sep;110(9):2875-2883.
3. Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). Br J Cancer. 2019 Jul;121(3):222-229.
4. Fukuda K, Mori K, Hasegawa N, Nasu K, Ishige K, Okamoto Y, Shiigai M, Abei M, Minami M, Hyodo I. Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide. Jpn J Radiol. 2019 Jul;37(7):555-563.
5. Sato Y, Yamada T, Hiroyama T, Sudo K, Hasegawa N, Hyodo I, Nakamura Y. A robust culture method for maintaining tumorigenic cancer stem cells in the hepatocellular carcinoma cell line Li-7. Cancer Sci. 2019 May;110(5):1644-1652.
6. Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells. Cancer Sci. 2019 Feb;110(2):639-649.
7. Shimizu K, Ohtaki Y, Okumura T, Boku N, Horio H, Takenoyama M, Yamashita M, Hyodo I, Mori K, Kondo H. Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases. J Thorac Cardiovasc Surg. 2019 May;157(5):2049-2057.
8. Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer. 2019 Jan;106:78-88.
9. Imanishi M, Yamamoto Y, Hamano Y, Yamada T, Moriwaki T, Gosho M, Okumura T, Boku N, Kondo H, Hyodo I. Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. Eur J Cancer. 2019 Jan;106:69-77.
10. Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. Oncologist. 2019 Mar;24(3):327-337.
11. Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. Gastric Cancer. 2019 Jan;22(1):138-146.
12. Iwamoto J, Murakami M, Monma T, Ueda H, Tamamushi M, Konishi N, Yara SI, Hirayama T, Ikegami T, Honda A, Mizokami Y. J Clin Biochem Nutr.
13. Current states of prevention of drug-induced gastroduodenal ulcer in real clinical practice: a cross-sectional study. 2020；66(2):158-162.
14. Terasaki A, Kurokawa H, P Indo H, Bando H, Hara H, J Majima H, Matsui H and Ito H. Enhancement of PDT-cytotoxicity via ROS induced by indomethacin in metastatic breast cancer. J Porphyr Phthalocyanine 23, 1440-1447, 2019 01 Nov
15. Kurokawa H, Ito H, Terasaki M, Matano D, Taninaka A, Shigekawa H and Matsui H. Nitric oxide regulates the expression of heme carrier protein-1 via hypoxia inducible factor-1α stabilization. Plos One 14, e0222074, 2019. September 12
16. Ito H, Kurokawa H, Suzuki H, P Indo H, J Majima H, Matsui H. 5-Aminolevulinic acid induced apoptosis via oxidative stress in normal gastric epithelial cells. J Clin Biochem Nutr 65, 83-90, 2019,September 01,
17. Kurokawa H, Ito H, Matsui H. The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation, Cells 8, 918, 2019, 17 Aug
18. Kurokawa H, Matsui H, Ito H, Taninaka A, Shigekawa H, Dodbiba G, Wei Y and Fujita T. Antioxidant Effect of Hydrogen Nanobubble Contributes to Suppression of Tumor Cell Growth, Biomed J Sci Tech Res 19, 14592-14594, 2019,July.22
19. Fujita T, Zhang L, Ponou J, Dodbiba G, Han Z, Wei Y, Kurokawa H and Matsui H. Nanobubble mixed solution of carbon dioxide and hydrogen for removing hydroxyl radical and superoxide anion free radicals in water. Int J Curr Adv Res 8. 19438-19442, 2019
20. Fujita T, Zhang L, Dodbiba G, Anh JW, Wei Y, Kurokawa H, Matsui H, Yamamoto S and Kawaguchi H, Production of the Hydroxyl Radical and Removal of Formaldehyde by Calcined Green Tuff Powder and Tile, Sustainability 11, 3390, 2019, 19 Jun
21. N. Oshida, T. Shida, S. Oh, T. Kim, T. Isobe, Y. Okamoto, T. Kamimaki, K.Okada, H. Suzuki, S. Ariizumi, M. Yamamoto, J. Shoda: Urinary Levels of Titin N-Fragment, a Skeletal Muscle Damage Marker, are Increased in Subjects with Nonalcoholic Fatty Liver Disease. Sci Rep, Vol. 9, 19498, 2019, DOI: 10.1038/s41598-019-56121-7, PMID 31862937
22. S. Hamada, J. Haruta, T. Haeno, T. Maeno, H. Suzuki, A. Takayashiki, H. Inada,T. Naito, M. Tomita, N. Kanou, T. Baba: Effectiveness of an interprofessional education program using team-based learning for medical students: A Randomized control trial. J Gen Fam Med, Vol.21, 2-9, 2019, DOI: 10.1002/jgf2.284, PMID: 31911883
23. H. Ito, H. Kurokawa, H. Suzuki, H. Indo, H. Majima, H.Matsui: 5-aminolevulinic acid induced apoptosis via oxidative stress in normal gastric epithelial cells. J Clin Biochem Nutr, Vol.65, 83-90, 2019, DOI: 10.3164/jcbn.18-46, PMID: 31592061
24. T. Ueno, H. Suzuki, M. Hirose, T. Shida, K. Ikezawa, H. Matsui, Y. Mizokami, A. Yanaka: Influence of Living Environment during Childhood on Helicobacter pylori Infection in Japanese Young Adults. Digestion, 1-6, 2019 (Corresponding author), DOI: 10.1159/000502574, PMID: 31550703
25. 鈴木 英雄、青木 利佳、吉村 理江、齋藤 洋子、溝上 裕士、中島 滋美: 方向性を重視した胃X線によるピロリ菌感染診断の学習効果についての検討、日本消化器がん検診学会雑誌、第57巻、554-560頁、2019、DOI: 10.11404/jsgcs.57.554
26. M. Naganuma, S. Sugimoto, H. Suzuki, Y. Matsuno, T. Araki, H. Shimizu, R.Hayashi, T. Fukuda, N. Nakamoto, H. Iijima, S. Nakamura, M. Kataoka, Y. Tamura, K. Tatsumi, T. Hibi, Y. Suzuki, T. Kanai; INDIGO survey Group: Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J Gastroenterol, Vol.54, 891-896, 2019, DOI: 10.1007/s00535-019-01591-9, PMID: 31102012
27. H. Suzuki, M. Mutho, T. Kamoshida, N. Kakinoki, S. Yoshida, T. Ebihara, M.Hirose, I. Hyodo, A. Yanaka: Chemoprevention Against Colon Cancer by Dietary Intake of Sulforaphane. Functional Foods in Health and Disease, Vol.9, 392-411, 2019, DOI: 10.31989/ffhd.v9i6.607
28. M. Fujita, Y. Ito-Fujita, T. Iyoda, M. Sasada, Y. Okada, K. Ishibashi, T.Osawa, H. Kodama, F. Fukai, H. Suzuki: Peptide TNIIIA2 Derived from Tenascin-C Contributes to Malignant Progression in Colitis-Associated Colorectal Cancer via β1-Integrin Activation in Fibroblasts. Int. J. Mol. Sci, Vol.20, E2752, 2019, DOI: 10.3390/ijms20112752, PMID: 31195598
29. K. Ikezawa, T. Kanamori, K. Iwai, K. Otsuka, M. Kobayashi, D. Ochi, H.Sugiyama, H. Suzuki, A. Soeda: Helicobacter pylori infection in rehabilitation staff younger than 35 years: Infection surveillance for three years. J Infect Prev, Vol.20, 240-245, 2019, DOI: 10.1177/1757177419852669
30. G. Yasuda, H. Ito, H. Kurokawa, M. Terasaki, H. Suzuki, Y. Mizokami, H. Matsui: The preventive effect of Qing Dai on bisphosphonate-induced gastric cellular injuries. J Clin Biochem Nutr, Vol.64, 45-51, 2019, DOI: 10.3164/jcbn.17-108, PMID: 30705511
31. Kobayashi K, Furumoto Y, Narasaka T.："Long-hood method" for identification of the bleeding site in colonic diverticular hemorrhage. Dig Endosc. 2020 Jan;32(1):e28-e29. doi:10.1111/den.13568. Epub 2019 Nov 18. PMID: 31736160
32. Hamano Y, Moriwaki T, To K, Watahiki T, Yamada T, Sakashita S, Hyodo I. A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression: A Case Report. Intern Med. 2019 Apr 15;58(8):1087-1091.
33. Moriwaki T, Sakai Y, Ishida H, Yamamoto Y, Endo S, Kuramochi H, Sato M, Hatachi Y, Bando Y, Maeba T, Ikezawa K, Shimada M, Amagai K, Morimoto M, Kobayashi K, Tsuji A, Nishina T, Hyodo I. Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER). Int J Clin Oncol. 2019 Oct;24(10):1214-1222. doi: 10.1007/s10147-019-01465-3. Epub 2019 May 14.
34. Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019 Nov;110(11):3565-3572.
35. Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. Int J Clin Oncol. 2019 Dec 14. doi: 10.1007/s10147-019-01600-0. Epub 2019 Dec 14.
36. Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 Jan;31(1):88-95.
37. Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, Tsuji A, Moriwaki T, Tanioka H, Shinozaki K, Uchino K, Yasui H, Tsukuda H, Nishikawa K, Ishida H, Yamanaka T, Yamazaki K, Hironaka S, Esaki T, Boku N, Hyodo I, Muro K. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020 Jun 10;38(17):1919-1927. doi: 10.1200/JCO.19.03077. Epub 2020 Mar 24.
38. Shimizu S, Okumura T, Oshiro Y, Fukumitsu N, Fukuda K, Ishige K, Hasegawa N, Numajiri H, Murofushi K, Ohnishi K, Mizumoto M, Nonaka T, Ishikawa H, Sakurai H. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy. Radiat Oncol. 2019 Dec 27;14(1):241. doi: 10.1186/s13014-019-1451-5.
39. Takahashi H, Sekino Y, Mori K, Okumura T, Nasu K, Fukuda K, Masuoka S, Iizumi T, Hasegawa N, Sakurai H, Minami M. Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. Br J Radiol. 2020 Jan;93(1105):20190375. doi: 10.1259/bjr.20190375.
40. Takahashi H, Mori K, Sekino Y, Okumura T, Hiyama T, Fukuda K, Hasegawa N, Sakai M, Kikuchi S, Takei Y, Iizumi T, Sakurai H, Minami M. Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy. J Oncol. 2019 Jul 4;2019:3580379. doi: 10.1155/2019/3580379.
41. Fukuda K, Mori K, Hasegawa N, Nasu K, Ishige K, Okamoto Y, Shiigai M, Abei M, Minami M, Hyodo I.Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide. Jpn J Radiol. 2019 Jul;37(7):555-563. doi: 10.1007/s11604-019-00843-1.
42. 山浦 正道, 福田 邦明, 森 健作, 廣瀬 優, 佐藤 雅志, 遠藤 壮登, 山田 武史, 長谷川 直之, 石毛 和紀, 兵頭 一之介, 溝上 裕士。仮性動脈瘤胆道穿破の2症例 胆道 (0914-0077)33巻4号 Page768-776(2019.10)
43. Shida T, Oshida N, Oh S, Okada K, Shoda J. Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes. 12:495-503, 2019.
44. Oshida N, Shida T, Oh S, Kim T, Isobe T, Okamoto Y, Kamimaki T, Okada K, Suzuki H, Ariizumi S, Yamamoto M, Shoda J. Urinary levels of Titin-N flagment, a skeletal muscle damage maker, are increased in subjects with Nonalcoholic fatty liver disease. Sci Rep 9 (1): 19498, 2019.
